It’s the same reason there isn’t a kyprolis trial, it’s too niche in MM the same way as the AML investigator trial. The broader Decitabine synergy trial is more realistic IMO.
the interest drop off in RC110 was real this was most likely Astex waiting for RC220. But first patient dosed is not the catalyst, rather P1A or first combo cohort.
Timing aligns, May 2024 in vitro results and blackout since June. If it didn’t happen quickly was never going to happen at all.
Only time will tell but if Astex don’t do a deal its never going to happen it will be overtaken by CPACS and left in the dust.
Drug supply agreement for RC220 combo would seem a bit redundant to warrant a 12 month blackout so mouse models and a development agreement perhaps @johndprent
Astex recent in licensing with Mosaic shows they will do deals, subject to safety and efficacy.
Link https://pharmatimes.com/news/mosaic-therapeutics-expands-pipeline-with-astex-deal/
Add to My Watchlist
What is My Watchlist?
